Zimmer Biomet Holdings, Inc.

Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet second quarter 2021 earnings conference call. If anyone needs assistance at any time during the conference, please press the star followed by the zero. As a reminder, this conference is being recorded today, August 3rd, 2021. Following today's presentation, there will be a question and answer session. At this time, all participants are in a listen-only mode. If you have a question, please press the star followed by the one on your push button phone. I would now like to turn the conference over to Carrie Maddox, Senior Vice President, Investor Relations, and Chief Communications Officer. Please go ahead.

Thank you, Operator, and good morning, everyone. I hope you are all well and safe. Welcome to Zimmer Biomet's second quarter 2021 earnings conference call. Joining me today are Brian Hanson, our Chairman, President, and CEO, and EVP and CFO, Suki Upadhyay. Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. Please note, we assume no obligation to update these forward-looking statements, even if actual results or future expectations change materially. Please refer to our SEC filings for a detailed discussion of these risks and uncertainties, in addition to the inherent limitations of such forward-looking statements. Additionally, the discussions on this call will include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included within our Q2 earnings release, which can be found on our website, ZimmerBiomet.com. With that, I'll now turn the call over to Brian. Brian?

All right, great. Thanks, Carrie. And thanks to everyone for joining us for our call this morning. As we're all aware, obviously, given the news recently, you know, COVID is still very much with us, and we're watching it very closely, as you can imagine. But, you know, given that even, you know, we've seen some real progress since our last call, and I think that's obvious to everybody. You know, the world has not returned to normalcy yet, but travel is returning. We have more team members in our offices, and I am personally looking forward to attending the AAOS meeting in about a month in San Diego. So really looking forward to that meeting. We have a lot of great technology that we're going to be able to showcase there and just really happy it's going to be in person again finally. I want to thank, you know, in that same vein, thank our team again for their dedication to safety. And really just across the board, their commitment to making all of our ZB manufacturing facilities and offices as safe as we possibly can. You know, you, you know, you, our team members are the driving force for this progress that we've seen in our own facilities and certainly in our communities as well. Also want to say that hope in our investor community that you're continuing to stay safe and have been hopefully able to travel over the last few months to see family and friends. This is an opportunity for us to take advantage of some travel as we begin to turn to more of a normal environment. Of course, not there yet, and we know this isn't happening inconsistently anyway in all regions. But overall, we are encouraged, and we're doing our part to keep this moving forward. And every single day, we are supporting our customers. and patients that they serve. And we're doing this safely, obviously, but this is a big focus for us as a mission-driven organization to be there for our customers so they can complete the procedures that they have and we can make sure that the patients receive the care that they deserve. And with that, I think it's a good lead-in to our Q2 call. Today, I'm just going to spend here in the beginning just a few minutes. on a couple of quick remarks, and then I'm going to turn it over to Suki, who's going to get right into a deeper view of our Q2 results, and I think most importantly, our 2021 guidance view on a go-forward basis. And then I'll come back to close out the call with some updates on our active portfolio management and product and pipeline highlights. I'll wait to do that after he provides the guidance information. So just to set him up a little bit, you know, overall, let me just say that our performance in the quarter is improved meaningfully from the first quarter of this year. You know, and that was pretty much across all regions and product categories. And as recovery from the global pandemic continued to take hold, we saw that recovery in our procedures also move in the right direction. You know, while we certainly anticipate some ongoing COVID pressure, we currently think it's going to be manageable by hospitals. And we expect that the, you know, the recovery will continue to build sequentially throughout the second half of 2021. Again, not out of the woods yet, But we do believe, thanks to the hospital's ability to better manage these COVID patients and the vaccine rollout continuing, we believe it will be manageable through the back half of the year, again, moving in the right direction. And with that, I'm going to turn it over to Sukhi for our financial update, and then I'll be back with you in a few minutes to close out the call before the Q&A.